veness of medicines between individuals and between different medicines, so sufficient consideration should be given to the effects of the other medicine.
•If you miss a dose, take a dose as soon as possible. If it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. You should never take two doses at one time.
•If you accidentally take more than your prescribed dose, consult with your doctor or pharmacist.
•Do not stop taking this medicine unless your doctor instructs you to do so.
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse effects (risks) as well as efficacies (benefits). It is important to minimize adverse effects and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
http://www.info.pmda.go.jp/go/pack/3929003C1067_1_04/3929003C1067_1_04?view=body#65
Kremezin, AST-120（クレメジンカプセル200mg）
Uremic Toxins
Uremic syndrome results from a malfunctioning of various organ systems due to the retention of compounds which, under normal conditions, would be excreted into the urine and/or metabolized by the kidneys. If these compounds are biologically active, they are called uremic toxins. One of the more important toxic effects of such compounds is cardio-vascular damage.5
Kremezin (AST-120) is an oral adsorbent that slows down the progression of chronic renal failure (CRF) by removing uremic toxins. This spherical carbonaceous adsorbent is composed of microcrystalline carbon with oxygen including surface oxides. It acts as surfactant and gastrointestinal agent.
Use of Kremezin
The oral adsorbent, AST-120 (Kremezin), can delay the progression of chronic renal failure in undialyzed patients with uremic syndrome.6
Recent studies show that Kremezin may have therapeutic potentials for the treatment of patients with various advanced glycation end products-related disorders such as diabetic microangiopathy, ischemic heart disease and neurodegenerative diseases.1 This orally administered adsorbent shows adsorption ability superior to activated charcoal for certain organic compounds that accumulate in patients with chronic kidney disease (CKD) and that are believed to accelerate the decline in kidney function.
http://www.info.pmda.go.jp/go/pack/3929003C1067_1_04/3929003C1067_1_04?view=body#65
